Protagenic Therapeutics (PTIX)
Developing PT00114 for stress-related neuropsychiatric disorders.
Something off on this page? Send us feedback.
Protagenic Therapeutics is a clinical-stage biopharmaceutical company developing peptide-based treatments for stress-related neuropsychiatric disorders. Its lead program, PT00114, targets the TCAP pathway and moved forward after Phase 1 safety and tolerability results, while the company has narrowed operations around that asset.
Protagenic Therapeutics develops peptide-based medicines for stress-related neuropsychiatric and mood disorders, with PT00114 as its lead clinical asset. PT00114 is a synthetic analogue of TCAP, a brain signaling peptide licensed from the University of Toronto, and is being studied for conditions such as treatment-resistant depression, anxiety, PTSD, and substance-use related stress biology. The company reported Phase 1 multiple-dose safety and tolerability data in healthy volunteers in December 2025 and has said it is preparing Phase 2 enrollment.
In 2026, Protagenic completed a separation from the Phytanix Bio acquisition and stated that it had refocused the organization around PT00114. Its shares moved from Nasdaq to OTC quotation after Nasdaq determined that continued listing requirements were not met, so the business depends on clinical execution, financing access, regulatory progress, and maintaining public reporting while operating as a very small development-stage biotech.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $566.0K · Total debt $0 · Total assets $2.1M · Shareholders' equity $1.7M
- Revenue
- $0
- Operating income
- −$961.2K
- Net income
- −$963.6K
No dividends on record.
| Institutions4 holders · as of Mar 31, 2026 | 3.70% | 66.9K shares | |
| Insiders2 holders · as of Aug 24, 2026 | 4.96% | 89.8K shares | |
| Otherremainder | 91.34% | 1.65M shares |
1.81M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Garo H. ArmenInsiderdirector, officer: EXEC. CHAIR & PRINCIPAL OFF | 4.06% | 73,533 | Form 4filed Aug 24, 2026 ↗ |
DRW Securities, LLCInstitution | 2.31% | 41,783 | 13Fas of Mar 31, 2026 |
FNY Investment Advisers, LLCInstitution | 1.38% | 25,000 | 13Fas of Mar 31, 2026 |
Barrett EvansInsiderdirector, 10 percent owner, officer: ex CEO | 0.90% | 16,233 | Form 4filed Oct 24, 2025 ↗ |
Corecap Advisors, LLCInstitution | 0.01% | 100 | 13Fas of Mar 31, 2026 |
| See all 10 → | |||
13F — a manager's quarterly holdings · Form 4 — an insider's transaction report
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 21, 2026 | Garo H. Armen | director, officer: EXEC. CHAIR & PRINCIPAL OFF | +20,000 | $0.6500 |
| Aug 20, 2026 | Garo H. Armen | director, officer: EXEC. CHAIR & PRINCIPAL OFF | +16,634 | $0.5898 |
| Aug 19, 2026 | Garo H. Armen | director, officer: EXEC. CHAIR & PRINCIPAL OFF | +2,700 | $0.3500 |
| Aug 11, 2026 | Garo H. Armen | director, officer: EXEC. CHAIR & PRINCIPAL OFF | +2,220 | $0.3200 |
| Aug 6, 2026 | Garo H. Armen | director, officer: EXEC. CHAIR & PRINCIPAL OFF | +685 | $0.2200 |
Not reported.